ALTHE.PA Theraclion SA
- Market cap
- EUR 51.7M
- P/E
- -
- P/B
- 3.21x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALTHE.PA undervalued?
Graham numberThe Graham number of Theraclion SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Theraclion SA fundamental analysis
2 of 11 checks passedROE 2/2
The stock's ROE exceeds expectations (1593.22%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.
ROA 0/2
The stock's ROA (-45.85%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 0/2
The stock's elevated P/BV ratio (26.97x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.
DER 0/2
The company has a high debt to equity ratio (461%), which means it owes a lot of money compared to what it actually owns, making it financially risky.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.
Assets Growth 2/2
With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.
Graham Number 0/1
Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.
Dividend Growth 0/2
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.
Dividend 0/2
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.
Buffet Intrinsic Value 0/1
Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Theraclion SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Theraclion SA
Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize image quality. The company was incorporated in 2004 and is h…
Full company profileTheraclion SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Theraclion SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.98M | 2.82M | 1.94M | 2.78M | 744K | 1.48M | 1.24M | 1.82M | 830K | 1.19M | 2.65M |
| Gross Profit | -2.70M | -2.40M | -2.53M | -4.02M | -3.81M | -4.54M | -3.05M | -1.08M | -7.18M | -6.21M | -17.2M |
| Operating Income | -7.49M | -7.10M | -6.98M | -4.52M | -4.29M | -4.74M | -6.31M | -3.15M | -6.96M | -6.37M | -15.7M |
| EBITDA | -7.18M | -6.77M | -6.51M | -4.38M | -4.15M | -4.40M | -5.74M | -4.49M | -5.92M | -5.98M | -15.7M |
| Net Income | -6.54M | -6.22M | -6.14M | -3.79M | -3.91M | -3.76M | -4.96M | -3.68M | -5.76M | -5.69M | -14.4M |
| EPS | -1.01 | -0.83 | -0.73 | -0.25 | -0.24 | -0.17 | -0.17 | -0.08 | -0.12 | -0.10 | -0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 14.7M | 13.8M | 9.56M | 10.5M | 10.5M | 11.8M | 13.9M | 18.7M | 11.5M | 12.5M | 14.8M |
| Total Liabilities | 9.13M | 10.3M | 10.1M | 10.6M | 13.8M | 13.1M | 13.4M | 13.0M | 11.5M | 15.1M | 15.2M |
| Shareholders' Equity | 5.58M | 3.47M | -532K | -79.7K | -3.24M | -1.27M | 545K | 5.65M | -114.00 | -2.59M | -395K |
| Cash & Short-term Investments | 6.93M | 4.89M | 939K | 1.40M | 2.35M | 2.49M | 2.52M | 7.82M | 4.17M | 3.38M | 5.22M |
| Total Debt | 661K | 673K | 53.0K | 424K | 10.6M | 2.39M | 2.51M | 1.95M | 1.30M | 5.09M | 4.95M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.97M | -6.79M | -4.73M | -3.69M | -3.32M | -3.88M | -5.27M | -2.48M | -2.91M | -7.16M | - |
| Capital Expenditure | 193K | 185K | 163K | 132K | 132K | 148K | 323K | 112K | 102K | 0.00 | 0.00 |
| Free Cash Flow | -8.16M | -6.97M | -4.89M | -3.82M | -3.45M | -4.03M | -5.59M | -2.60M | -3.01M | -7.16M | - |
| Ratios | |||||||||||
| ROE | -117.1% | -179.4% | - | - | - | - | -911.1% | -65.1% | - | - | - |
| ROA | -44.4% | -45.2% | -64.2% | -36.1% | -37.0% | -31.8% | -35.6% | -19.7% | -50.2% | -45.5% | -97.6% |
| Net Profit Margin | -330.9% | -220.4% | -316.8% | -136.2% | -524.9% | -253.9% | -401.8% | -201.7% | -693.6% | -479.8% | -543.9% |
| Debt to Equity | 0.12x | 0.19x | - | - | - | - | 4.61x | 0.35x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Theraclion SA dividends
Theraclion SA has not paid dividends in the last 9 fiscal years.
Last stock split: 367:350 on Jul 26, 2016.
Who owns Theraclion SA
- Insiders 67.76%
- Institutions 0.00%
- Public & others 32.24%
- Shares outstanding 73.8M
- Free float 32.3M
Theraclion SA company profile
- Company name
- Theraclion SA
- Ticker
- ALTHE.PA
- ISIN
- FR0010120402
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 40
- Fiscal year end
- December
- Address
- 244, avenue Pierre Brossolette, Malakoff, France, 92240
- Phone
- 33 1 55 48 90 70
- Website
- theraclion.com
About Theraclion SA
Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize image quality. The company was incorporated in 2004 and is headquartered in Malakoff, France.
Theraclion SA management
6- Mr. Martin DeterreGM & CEO
- Julie VeisseireAdministrative and Financial Director & CFO
- Ms. Alexandra RocherVice President of Operations
- Jérémie AnquezVP Research & Chief Scientific Officer
- Thibault Le NormandDirector of Sales, Marketing & Applications
- Dr. Michel Nuta M.D.VP of Veins & Chief Medical Officer